Press Release: aap: Good start in 2015 with sales and EBITDA increase; growth drivers in Q1 were LOQTEQ(R) (+ 45%) und Biomaterials (+ 23%)

aap Implantate AG / aap: Good start in 2015 with sales and EBITDA increase; growth drivers in Q1 were LOQTEQ(R) (+ 45%) und Biomaterials (+ 23%) . Processed and transmitted by Nasdaq OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

aap

Implantate AG (XETRA: AAQ.DE) had a successful start to the 2015 fiscal year, showing growth in sales and EBITDA and achieving its financial targets. The company increased its sales during the first quarter of the 2015 fiscal year by 16% to EUR 7.1 million compared with the same period in the previous year (Q1/2014: EUR 6.1 million). The EBITDA grew by 91% to EUR 0.2 million during the reporting period in comparison to the first three months of 2014 (Q1/2014: EUR 0.1 million).

in EUR million Q1/2015 Q1/2014 Change Trauma 2.5 2.2 15% thereof LOQTEQ(R) 1.7 1.1 45% Biomaterials 4.4 3.6 23% Projects 0.1 0.1 109% Other 0.1 0.2 -81% Sales 7.1 6.1 16%

in EUR million Q1/2015 Q1/2014 Change EBITDA 0.2 0.1 91% EBIT -0.4 -0.4 -3%

On a comparable basis (excluding one-time costs in connection with strategic measures and project revenues and thus with associated costs in each case), normalized sales in the first quarter of 2015 amounted to EUR 7.0 million (Q1/2014: EUR 6.1 million) and normalized EBITDA to EUR 0.3 million (Q1/2014: EUR 0.1 million).

The following highlights show the progress that aap Implantate AG achieved in the first quarter of 2015 with regard to the implementation of the 2015 Management Agenda:

-- Financial targets were achieved: sales amounting to EUR 7.1 million and EBITDA of EUR 0.2 million exceed the guidance issued in February of EUR 6.5 million to EUR 7.0 million (sales) and EUR -0.5 million to EUR 0.1 million (EBITDA)

-- Growth drivers in sales revenues are LOQTEQ(R) with +45% to EUR 1.7 million and the Biomaterials business with +23% to EUR 4.4 million

-- LOQTEQ(R): European key patent obtained for LOQTEQ(R) core technology; progress in the expansion of LOQTEQ(R) product portfolio is on schedule

-- US distribution: advanced discussions with various distributors and the potential conclusion of a contract in Q2/2015 and initial sales in the second half of 2015

-- Silver coating technology: important European patent obtained for silver coating as well as corresponding technology and coating apparatuses

-- Biomaterials: various negotiations with globally active medtech companies with regard to the ongoing targeted expansion of the bone cement business

Outlook for 2015

With regard to the development of the US market, aap Implantate AG's negotiations with potential distribution partners for sales of its trauma products are at an advanced stage. In the process the company is using a hybrid distribution model: the products are to be sold locally through stocking (distributor buys the products) and through non-stocking distributors (products are placed with the distributor and payment is based on respective consumption). aap Implantate AG is expecting first sales on the US market in the second half of 2015. In addition, in the trauma business the market launch of the LOQTEQ(R) fibula plate and the product launch of the new polyaxial LOQTEQ(R) radius plate system are scheduled for the second quarter of 2015. In the silver coating technology area, all approval-related work continues on schedule and the company is aiming to submit the CE approval application for the first silver-coated products in the second half of 2015. Immediately following the CE approval application the FDA approval application will be submitted in a next step.

Furthermore, the Management Board confirms its sales and EBITDA forecast for the full year of 2015. The company continues to anticipate sales between EUR 33 million and EUR 35 million and an EBITDA between EUR 2.5 million and EUR 3.5 million.

For the second quarter of 2015, aap Implantate AG is expecting sales to range between EUR 5.0 million and EUR 6.1 million and an EBITDA of EUR -1.5 million to EUR -1.0 million. This is a quarterly fluctuation that is in particular influenced by the ordering behavior of our major customers in the area of bone cement and mixing systems. In this regard, it should be noted that the development of the most important key figures should be evaluated as an overall economic review on an annual basis rather than on a quarterly basis.

About aap Implantate AG

aap Implantate AG is a globally operating medical device company headquartered in Berlin, Germany. The company develops, manufactures and markets trauma and biomaterials products for orthopedics. The trauma portfolio includes besides the innovative anatomical plating system LOQTEQ(R) a wide range of cannulated screws as well as standard plates and screws. In the biomaterials business the company is specialized on bone cements and mixing systems. In German-speaking countries aap Implantate AG directly sells its trauma products to hospitals, buying syndicates and hospital groups while it uses a broad network of distributors in more than 60 countries at the international level. In the biomaterials business sales are handled via OEM and private label cooperations with several selected international orthopedic and trauma companies. aap Implantate AG's stock is listed in the Prime Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play.

Forward-looking statement

This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.

For inquiries please contact: aap Implantate AG, Fabian Franke, Investor Relations, Lorenzweg 5, 12099 Berlin, Germany

Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, e-mail: f.franke@aap.de

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: aap Implantate AG via Globenewswire

HUG#1921925

--- End of Message ---

aap Implantate AG

Lorenzweg 5 Berlin Germany

WKN: 506660;ISIN: DE0005066609;

Listed: Freiverkehr in Börse Stuttgart,

Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,

Freiverkehr in Börse Berlin,

Freiverkehr in Börse Düsseldorf,

Freiverkehr in Bayerische Börse München,

Freiverkehr in Niedersächsische Börse zu Hannover,

Prime Standard in Frankfurter Wertpapierbörse,

Regulierter Markt in Frankfurter Wertpapierbörse;

http://www.aap.de (END) Dow Jones Newswires

   May 15, 2015 17:56 ET (21:56 GMT)- - 05 56 PM EDT 05-15-15